| Primary |
| Drug Use For Unknown Indication |
27.6% |
| Product Used For Unknown Indication |
14.5% |
| Bronchitis |
11.8% |
| Respiratory Disorder |
9.2% |
| Pyrexia |
6.6% |
| Benign Prostatic Hyperplasia |
2.6% |
| Bladder Disorder |
2.6% |
| Diabetes Mellitus |
2.6% |
| Nasopharyngitis |
2.6% |
| Prophylaxis |
2.6% |
| Seasonal Allergy |
2.6% |
| Sinusitis |
2.6% |
| Substance Use |
2.6% |
| Antiallergic Therapy |
1.3% |
| Arthralgia |
1.3% |
| Blood Pressure |
1.3% |
| Breast Cancer |
1.3% |
| Cardiomegaly |
1.3% |
| Cellulitis |
1.3% |
| Chemotherapy |
1.3% |
|
| Benign Prostatic Hyperplasia |
13.2% |
| Stevens-johnson Syndrome |
13.2% |
| Drug Toxicity |
10.5% |
| Peptic Ulcer |
7.9% |
| Cardio-respiratory Arrest |
5.3% |
| Respiratory Arrest |
5.3% |
| Somnolence |
5.3% |
| Tremor |
5.3% |
| Visual Field Defect |
5.3% |
| Chronic Obstructive Pulmonary Disease |
2.6% |
| Completed Suicide |
2.6% |
| Confusional State |
2.6% |
| Cyanosis |
2.6% |
| Death |
2.6% |
| Disseminated Intravascular Coagulation |
2.6% |
| Drug Abuse |
2.6% |
| Drug Interaction |
2.6% |
| Dry Skin |
2.6% |
| Dyspnoea |
2.6% |
| Epistaxis |
2.6% |
|
| Secondary |
| Product Used For Unknown Indication |
34.6% |
| Drug Use For Unknown Indication |
30.3% |
| Premedication |
6.4% |
| Pain |
6.2% |
| Breast Cancer |
2.6% |
| Drug Exposure During Pregnancy |
2.0% |
| Prophylaxis |
2.0% |
| Pruritus |
1.7% |
| Prophylaxis Of Nausea And Vomiting |
1.6% |
| Bronchitis |
1.5% |
| Breast Cancer Metastatic |
1.3% |
| Metastases To Bone |
1.3% |
| Respiratory Tract Infection |
1.3% |
| Breast Cancer Recurrent |
1.1% |
| Maternal Therapy To Enhance Foetal Lung Maturity |
1.1% |
| Nasopharyngitis |
1.0% |
| Procedural Pain |
1.0% |
| Anaesthesia |
0.9% |
| Crohn's Disease |
0.9% |
| Ill-defined Disorder |
0.9% |
|
| Jaundice |
11.1% |
| Venoocclusive Liver Disease |
10.2% |
| Completed Suicide |
9.3% |
| Death |
6.5% |
| Venoocclusive Disease |
6.5% |
| Respiratory Arrest |
6.0% |
| Premature Baby |
5.6% |
| Drug Toxicity |
4.6% |
| Tachycardia |
4.6% |
| Vomiting |
4.2% |
| Dyspnoea |
3.7% |
| Cardiac Arrest |
3.2% |
| Cardio-respiratory Arrest |
3.2% |
| Overdose |
3.2% |
| Somnolence |
3.2% |
| Stevens-johnson Syndrome |
3.2% |
| Toxic Epidermal Necrolysis |
3.2% |
| Drug Abuse |
2.8% |
| Intentional Overdose |
2.8% |
| Pustular Psoriasis |
2.8% |
|
| Concomitant |
| Product Used For Unknown Indication |
50.8% |
| Prophylaxis |
7.5% |
| Premedication |
6.4% |
| Drug Use For Unknown Indication |
5.0% |
| Infection Prophylaxis |
4.4% |
| Hypertension |
3.5% |
| Constipation |
3.2% |
| Aplastic Anaemia |
2.1% |
| Insomnia |
1.9% |
| Acute Myeloid Leukaemia |
1.8% |
| Antifungal Prophylaxis |
1.7% |
| Pain |
1.6% |
| Nausea |
1.5% |
| Graft Versus Host Disease |
1.4% |
| Bone Marrow Conditioning Regimen |
1.3% |
| Acute Graft Versus Host Disease |
1.3% |
| Rheumatoid Arthritis |
1.3% |
| Pyrexia |
1.2% |
| Prophylaxis Against Graft Versus Host Disease |
1.1% |
| Antiviral Prophylaxis |
1.1% |
|
| Pyrexia |
9.5% |
| Vomiting |
8.3% |
| Thrombocytopenia |
8.1% |
| Staphylococcal Sepsis |
7.9% |
| White Blood Cell Count Decreased |
7.1% |
| Fungal Infection |
6.6% |
| Rash |
5.0% |
| Pneumonia |
4.4% |
| Urticaria |
4.4% |
| Death |
4.1% |
| Epstein-barr Virus Associated Lymphoproliferative Disorder |
3.9% |
| Toxic Epidermal Necrolysis |
3.7% |
| Febrile Neutropenia |
3.5% |
| Respiratory Failure |
3.5% |
| Tachycardia |
3.5% |
| Pulmonary Embolism |
3.3% |
| Sepsis |
3.3% |
| Stevens-johnson Syndrome |
3.3% |
| White Blood Cell Count Increased |
3.3% |
| Infusion Related Reaction |
3.1% |
|
| Interacting |
| Infection |
17.6% |
| Analgesic Therapy |
11.8% |
| Ill-defined Disorder |
11.8% |
| Product Used For Unknown Indication |
11.8% |
| Abnormal Behaviour |
5.9% |
| Autism |
5.9% |
| Crohn's Disease |
5.9% |
| Drug Use For Unknown Indication |
5.9% |
| Headache |
5.9% |
| Pain |
5.9% |
| Relaxation Therapy |
5.9% |
| Seasonal Allergy |
5.9% |
|
| Urinary Tract Infection |
42.9% |
| Drug Interaction |
14.3% |
| Headache |
14.3% |
| Stereotypy |
14.3% |
| Therapeutic Response Delayed |
14.3% |
|
